» Articles » PMID: 35131876

The Anti-Nectin 4: A Promising Tumor Cells Target. A Systematic Review

Overview
Journal Mol Cancer Ther
Date 2022 Feb 8
PMID 35131876
Authors
Affiliations
Soon will be listed here.
Abstract

The Nectin cell adhesion protein 4 (Nectin-4) is overexpressed in multiple human malignancies. Such aberrant expression is correlated with cancer progression and poor prognostic. Nectin-4 has emerged as a potential biomarker and promising targeted therapy. This review aimed to gather the current state of the literature about Nectin-4 relevance in preclinical tumor models and to summarize its clinical relevance regarding cancer. A systematic assessment of literature articles was performed by searching in PUBMED (MEDLINE) from the database inception to May 2021, following PRISMA guidelines. Preclinical models unanimously demonstrated membrane and cytoplasmic location of the Nectin-4. Furthermore, Nectin-4 was overexpressed whatever the location of the solid tumors. Interestingly, a heterogeneity of Nectin-4 expression has been highlighted in bladder urothelial carcinoma. High serum Nectin-4 level was correlated with treatment efficiency and disease progression. Finally, generated anti-drug-conjugated targeting Nectin-4 induced cell death in multiple tumor cell lines. Nectin-4 emerges as a promising target for anticancer drugs development because of its central role in tumorigenesis, and lymphangiogenesis. Enfortumab vedotin targeting Nectin-4 demonstrated encouraging results and should be extended to other types of solid tumors.

Citing Articles

Immunoconjugates as an Efficient Platform for Drug Delivery: A Resurgence of Natural Products in Targeted Antitumor Therapy.

Mihaylova R, Momekova D, Elincheva V, Momekov G Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770542 PMC: 11677665. DOI: 10.3390/ph17121701.


Emerging Targets in Non-Small Cell Lung Cancer.

Liu L, Soler J, Reckamp K, Sankar K Int J Mol Sci. 2024; 25(18).

PMID: 39337530 PMC: 11432526. DOI: 10.3390/ijms251810046.


Mechanistic Insights into the Successful Development of Combination Therapy of Enfortumab Vedotin and Pembrolizumab for the Treatment of Locally Advanced or Metastatic Urothelial Cancer.

Taylor C, Patterson K, Friedman D, Bacot S, Feldman G, Wang T Cancers (Basel). 2024; 16(17).

PMID: 39272928 PMC: 11393896. DOI: 10.3390/cancers16173071.


Exploring membranous NECTIN-4 expression patterns and enfortumab vedotin response in prostate cancer.

Weiten R, Bernhardt M, Niemann M, Kristiansen G, Grunwald V, Ritter M J Cell Mol Med. 2024; 28(14):e18572.

PMID: 39072867 PMC: 11284121. DOI: 10.1111/jcmm.18572.


Opportunities and Challenges in the Development of Antibody-Drug Conjugate for Triple-Negative Breast Cancer: The Diverse Choices and Changing Needs.

Tang Q, Li H, Zhao X, Li Z, Ma C, Zhou S World J Oncol. 2024; 15(4):527-542.

PMID: 38993251 PMC: 11236369. DOI: 10.14740/wjon1853.